{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:59:36Z","timestamp":1790683176654,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jpba.2018.03.024","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T16:00:59Z","timestamp":1521388859000},"page":"245-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["A UHPLC\u2013MS\/MS-based method for the simultaneous monitoring of eight antiblastic drugs in plasma and urine of exposed healthcare workers"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-7569","authenticated-orcid":false,"given":"Viviana","family":"Izzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-3220","authenticated-orcid":false,"given":"Bruno","family":"Charlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-2752","authenticated-orcid":false,"given":"Elena","family":"Bloise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Pingeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2710-1296","authenticated-orcid":false,"given":"Alfonso","family":"Vietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Dal Piaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpba.2018.03.024_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2042098616672572","article-title":"Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital","volume":"8","author":"Wahlang","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.jpba.2018.03.024_bib0010","series-title":"Monographs on the Evaluation of Carcinogenic Risk to Humans. Complete List of Agents Evaluated and Their Classification","author":"International Agency for Research on Cancer (IARC)","year":"2018"},{"key":"10.1016\/j.jpba.2018.03.024_bib0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10661-016-5762-9","article-title":"Environmental monitoring by surface sampling for cytotoxics: a review","volume":"189","author":"Marie","year":"2017","journal-title":"Environ. Monit. Assess."},{"issue":"9","key":"10.1016\/j.jpba.2018.03.024_bib0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/JOM.0000000000000249","article-title":"Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence","volume":"56","author":"Connor","year":"2014","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.jpba.2018.03.024_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1078155210388462","article-title":"Exposure to hazardous drugs in healthcare: an issue that will not go away","volume":"17","author":"Davis","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jpba.2018.03.024_bib0030","series-title":"NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings","author":"National Institute for Occupational Safety and Health","year":"2018"},{"issue":"11","key":"10.1016\/j.jpba.2018.03.024_bib0035","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/15459624.2014.916809","article-title":"Adherence to safe handling guidelines by health care workers who administer antineoplastic drugs","volume":"11","author":"Boiano","year":"2014","journal-title":"J. Occup. Environ. Hyg."},{"key":"10.1016\/j.jpba.2018.03.024_bib0040","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/JOM.0b013e3181f73ae6","article-title":"Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs","volume":"52","author":"McDiarmid","year":"2010","journal-title":"J. Occup. Environ. Med."},{"issue":"4","key":"10.1016\/j.jpba.2018.03.024_bib0045","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2011.12.030","article-title":"Occupational exposures among nurses and risk of spontaneous abortions","volume":"206","author":"Lawson","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jpba.2018.03.024_bib0050","first-page":"855","article-title":"Leukaemia and reproductive outcome among nurses handling antineoplastic drugs","volume":"49","author":"Skov","year":"1992","journal-title":"Br. J. Ind. Med."},{"issue":"4","key":"10.1016\/j.jpba.2018.03.024_bib0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.aogh.2014.08.001","article-title":"Hazards of the Health care sector: looking beyond Infectious disease","volume":"80","author":"McDiarmid","year":"2014","journal-title":"Ann. Glob. Health"},{"key":"10.1016\/j.jpba.2018.03.024_bib0060","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3322\/canjclin.56.6.354","article-title":"Preventing occupational exposures to antineoplastic drugs in healthcare settings","volume":"56","author":"Connor","year":"2006","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jpba.2018.03.024_bib0065","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00002820-199308000-00005","article-title":"Acute symptoms associated with antineoplastic drug handling among nurses","volume":"16","author":"Valanis","year":"1993","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.jpba.2018.03.024_bib0070","first-page":"455","article-title":"Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel","volume":"50","author":"Valanis","year":"1993","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.jpba.2018.03.024_bib0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1078155210361431","article-title":"Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device","volume":"17","author":"Sessink","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jpba.2018.03.024_bib0080","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1310\/hpj4803-204","article-title":"Reduction in surface contamination with cyclophosphamide in 30 hospital pharmacies following implementation of a closed-system drug transfer device","volume":"48","author":"Sessink","year":"2013","journal-title":"Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.jpba.2018.03.024_bib0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1539\/joh.50.48","article-title":"Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department","volume":"50","author":"Castiglia","year":"2008","journal-title":"J. Occup. Health"},{"issue":"6 Pt 2","key":"10.1016\/j.jpba.2018.03.024_bib0090","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/sj.jea.7500142","article-title":"Assessing children's exposure to hazardous environmental chemicals: an overview of selected research challenges and complexities","volume":"10","author":"Needham","year":"2000","journal-title":"J. Expo. Anal. Environ. Epidemiol."},{"issue":"8","key":"10.1016\/j.jpba.2018.03.024_bib0095","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1289\/ehp.7617","article-title":"Biologic monitoring of exposure to environmental chemicals throughout the life stages: requirements and issues for consideration for the National Children\u2019s Study","volume":"113","author":"Barr","year":"2005","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jpba.2018.03.024_bib0100","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jchromb.2017.06.028","article-title":"A review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workers","volume":"1060","author":"Mathias","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"1","key":"10.1016\/j.jpba.2018.03.024_bib0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1078155212451196","article-title":"Determination of exposure of dispensary drug preparers to cyclophosphamide by passive sampling and liquid chromatography with tandem mass spectrometry","volume":"19","author":"Wakui","year":"2013","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"17","key":"10.1016\/j.jpba.2018.03.024_bib0110","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/rcm.3657","article-title":"Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography\/electrospray ionization tandem mass spectrometry: bioanalytical method validation","volume":"22","author":"Sottani","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2018.03.024_bib0115","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00420-015-1026-1","article-title":"Antineoplastic drug contamination in the urine of Canadian healthcare workers","volume":"88","author":"Hon","year":"2015","journal-title":"Int. Arch. Occup. Environ. Health"},{"key":"10.1016\/j.jpba.2018.03.024_bib0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jchromb.2012.02.039","article-title":"Development and validation of LC\u2013MS\/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine","volume":"893\u2013894","author":"Dubbelman","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.03.024_bib0125","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/rcm.1508","article-title":"Quantification of cyclo-phosphamide and its metabolites in urine using liquid chromatography\/tandem mass spectrometry","volume":"18","author":"Kasel","year":"2004","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"2","key":"10.1016\/j.jpba.2018.03.024_bib0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0961203317717631","article-title":"Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease","volume":"27","author":"Iudici","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jpba.2018.03.024_bib0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1078155210389215","article-title":"Sampling and mass spectrometric analytical methods for five anti-neoplastic drugs in the healthcare environment","volume":"18","author":"Pretty","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jpba.2018.03.024_bib0140","unstructured":"EMEA\/CHMP\/EWP\/192217\/2009, Guideline on Bioanalytical Method Validation, The European Medicines Agency, 2011."},{"key":"10.1016\/j.jpba.2018.03.024_bib0145","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/bmc.3684","article-title":"Dispersive solid-phase extraction procedure coupled to UPLC-ESI\u2013MS\/MS analysis for the simultaneous determination of thirteen cytotoxic drugs in human urine","volume":"30","author":"Fabrizi","year":"2016","journal-title":"Biomed. Chromatogr."},{"issue":"4","key":"10.1016\/j.jpba.2018.03.024_bib0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00003088-199733040-00001","article-title":"Clinical pharmacokinetics of irinotecan","volume":"33","author":"Chabot","year":"1997","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518302267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518302267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T01:51:07Z","timestamp":1549331467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518302267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":30,"alternative-id":["S0731708518302267"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.03.024","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A UHPLC\u2013MS\/MS-based method for the simultaneous monitoring of eight antiblastic drugs in plasma and urine of exposed healthcare workers","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}